Lesson plan

Etamivan

Etamivan (INN, or ethamivan (USAN); trade names Analepticon, Emivan, and Vandid) is a respiratory stimulant drug related to nikethamide. It was mainly used in the treatment of barbiturate overdose and chronic obstructive pulmonary disease, but has now largely fallen into disuse. Adverse effects which are common to the respiratory stimulant class include sneezing, coughing, and laryngospasm when infused too rapidly. More serious adverse events include muscle twitching, tremors, and convulsions. The dose to treat barbiturate intoxication or carbon dioxide narcosis in adults ranges from 0.5 mg/kg to 5.0 mg/kg, infused intravenously over several minutes. Epilepsy and the use of monoamine oxidase inhibitors or other adrenergic drugs are contraindications.

Back to article

Article summary

Etamivan (INN, or ethamivan (USAN); trade names Analepticon, Emivan, and Vandid) is a respiratory stimulant drug related to nikethamide. It was mainly used in the treatment of barbiturate overdose and chronic obstructive pulmonary disease, but has now largely fallen into disuse. Adverse effects which are common to the respiratory stimulant class include sneezing, coughing, and laryngospasm when infused too rapidly. More serious adverse events include muscle twitching, tremors, and convulsions. The dose to treat barbiturate intoxication or carbon dioxide narcosis in adults ranges from 0.5 mg/kg to 5.0 mg/kg, infused intravenously over several minutes. Epilepsy and the use of monoamine oxidase inhibitors or other adrenergic drugs are contraindications.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.